Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC19225PD-1-IN-1 (CA-170)CAS: 1673534-76-3纯度: >99.00% / >98.00%
PD-1-IN-1 (CA-170) 是一种具有口服活性的免疫检查点调节蛋白VISTA和PD-L1双重抑制剂。
- GC19268NVP-HDM201CAS: 1448867-41-1纯度: >98.00%
NVP-HDM201 (NVP-HDM201) 是一种有效的、口服生物利用度高且高度特异性的 p53-MDM2 相互作用抑制剂。
- GC19306RAD51 Inhibitor B02CAS: 1290541-46-6纯度: >99.50%
RAD51 Inhibitor B02是一种人RAD51重组酶的特异性抑制剂(IC 50 值为27.4μM),对大肠杆菌中的同系物RecA没有抑制作用(IC 50 >250μM)。
- GC19531PembrolizumabCAS: 1374853-91-4纯度: >99.00% / >98.00%
Pembrolizumab 是一种抗程序性死亡 1 单克隆抗体,已在晚期实体癌患者中证明具有临床显着的抗肿瘤活性和可接受的安全性,并已被美国 FDA 批准用于治疗晚期黑色素瘤、NSCLC、头颅和脑肿瘤。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC19225 | PD-1-IN-1 (CA-170) | 1673534-76-3 | >99.00% / >98.00% | |
PD-1-IN-1 (CA-170) 是一种具有口服活性的免疫检查点调节蛋白VISTA和PD-L1双重抑制剂。 | ||||
| GC19248 | Mivebresib | 1445993-26-9 | >99.00% | |
A BRD2, BRD4, and BRDT inhibitor | ||||
| GC19254 | ML385 | 846557-71-9 | >98.00% / >99.50% | |
ML385是一种特定的核因子红细胞2相关因子2(NRF2)抑制剂。 | ||||
| GC19257 | MX69 | 1005264-47-0 | >99.50% | |
An inhibitor of the MDM2 protein and XIAP RNA interaction | ||||
| GC19263 | NKP-1339 | 197723-00-5 | >98.00% | |
A ruthenium complex with anticancer activity | ||||
| GC19268 | NVP-HDM201 | 1448867-41-1 | >98.00% | |
NVP-HDM201 (NVP-HDM201) 是一种有效的、口服生物利用度高且高度特异性的 p53-MDM2 相互作用抑制剂。 | ||||
| GC19290 | PF-3084014 | 1290543-63-3 | >98.00% | |
An inhibitor of γ-secretase | ||||
| GC19293 | PFK-158 | 1462249-75-7 | >98.00% | |
PFK-158 是一种有效的选择性 PFKFB3 抑制剂,通过减少癌细胞中葡萄糖的摄取、ATP 的产生、乳酸的释放以及诱导细胞凋亡和自噬,显示出广泛的抗肿瘤活性.PFK-158 在 EC 细胞中以剂量和时间依赖性方式抑制细胞活力。 | ||||
| GC19306 | RAD51 Inhibitor B02 | 1290541-46-6 | >99.50% | |
RAD51 Inhibitor B02是一种人RAD51重组酶的特异性抑制剂(IC 50 值为27.4μM),对大肠杆菌中的同系物RecA没有抑制作用(IC 50 >250μM)。 | ||||
| GC19312 | RO8994 | 1309684-94-3 | >99.00% | |
An inhibitor of MDM2-p53 interaction | ||||
| GC19346 | Talampanel | 161832-65-1 | >98.00% | |
An allosteric AMPA receptor antagonist | ||||
| GC19348 | TAS-102 | 733030-01-8 | >98.00% | |
An orally bioavailable combination of a nucleoside analog and TPase inhibitor | ||||
| GC19398 | PIM447 | 1210608-43-7 | - | |
PIM447 (LGH447) 是一种有效的、口服的、选择性的泛 PIM 激酶抑制剂,对 PIM1、PIM2 和 PIM3 的 Ki 值分别为 6、18 和 9 pM。 PIM447 具有双重抗骨髓瘤和骨保护作用。 PIM447 诱导细胞凋亡。 | ||||
| GC19411 | IITZ-01 | 1807988-47-1 | >99.00% | |
IITZ-01 是一种有效的溶酶体自噬抑制剂,具有单剂抗肿瘤活性,对 PI3Kγ 的 IC50 为 2.62 μM。 | ||||
| GC19436 | CID-5721353 | 301356-95-6 | >98.00% | |
A Bcl-6 inhibitor | ||||
| GC19452 | AMG-176 | 1883727-34-1 | >99.00% | |
AMG-176 (Tapotoclax) 是一种有效的、选择性的、具有口服活性的 MCL-1 抑制剂,Ki 为 0.13 nM。 | ||||
| GC19457 | Trolox | 53188-07-1 | >98.00% | |
Vitamin E derivative with antioxidant properties | ||||
| GC19485 | DC661 | 1872387-43-3 | >98.00% | |
DC661是一种能够抑制棕榈酰蛋白硫酯酶1(PPT1)并有效抑制细胞自噬的小分子化合物,可作为抗溶酶体剂。 | ||||
| GC19503 | GSK547 | 2226735-55-1 | >99.50% | |
GSK547 (GSK'547) 是受体相互作用的丝氨酸/苏氨酸蛋白激酶 1 (RIPK1) 的高选择性和强效抑制剂,可抑制巨噬细胞介导的胰腺癌适应性免疫耐受。 | ||||
| GC19522 | Sodium oleate | 143-19-1 | >97.00% | |
A monounsaturated fatty acid | ||||
| GC19528 | 1,4-Benzoquinone | 106-51-4 | >99.00% | |
A toxic metabolite of benzene | ||||
| GC19531 | Pembrolizumab | 1374853-91-4 | >99.00% / >98.00% | |
Pembrolizumab 是一种抗程序性死亡 1 单克隆抗体,已在晚期实体癌患者中证明具有临床显着的抗肿瘤活性和可接受的安全性,并已被美国 FDA 批准用于治疗晚期黑色素瘤、NSCLC、头颅和脑肿瘤。 | ||||
| GC19533 | Infliximab | 170277-31-3 | >98.00% / >98.50% | |
英夫利昔单抗是一种嵌合单克隆 IgG1 抗体,可特异性结合 TNF-α。 | ||||
| GC19537 | β-Elemene | 515-13-9 | >99.50% / >98.00% | |
β-Elemene是从天然植物温郁金( Curcuma aromatica )中提取的一种单萜类化合物,具有抗肿瘤活性。 | ||||
